MiRagen releases Phase 1 clinical data of cobomarsen

BOULDER — MiRagen Therapeutics Inc. (Nasdaq: MGEN), a Boulder-based biotech company focused on RNA-targeted therapies, has announced new data on its Phase 1 clinical trial for its drug cobomarsen.

Cobomarsen is an inhibitor of miR-155. The Phase 1 trial investigated the safety, tolerability and efficacy of the drug in 43 patients with mycosis fungoides. The trial monitored the patients for 23 months as they received doses of the drug. The study found that 92 percent of patients had improvement in tumor burden and that the drug was generally well-tolerated.

“We are excited to present final data from our Phase 1 cobomarsen clinical trial, which continue to show that cobomarsen is safe and well-tolerated, has relevant biological and clinical activity in patients and has the potential to impact the quality of life for MF patients,” Paul Rubin, MiRagen executive vice president of R&D, said in a prepared statement. “We believe the Phase 1 data has provided us with the means and the confidence to design and implement a larger controlled trial in MF patients.”

BOULDER — MiRagen Therapeutics Inc. (Nasdaq: MGEN), a Boulder-based biotech company focused on RNA-targeted therapies, has announced new data on its Phase 1 clinical trial for its drug cobomarsen.

Cobomarsen is an inhibitor of miR-155. The Phase 1 trial investigated the safety, tolerability and efficacy of the drug in 43 patients with mycosis fungoides. The trial monitored the patients for 23 months as they received doses of the drug. The study found that 92 percent of patients had improvement in tumor burden and that the drug was generally well-tolerated.

“We are excited to present final data from our Phase 1 cobomarsen clinical trial, which continue to show that cobomarsen is safe and well-tolerated, has relevant biological and clinical activity in patients and has the potential to impact the quality of life for MF patients,” Paul Rubin, MiRagen executive vice president of R&D, said in a prepared statement. “We believe the Phase 1 data has provided us with the means and the confidence to design and implement a larger controlled trial in MF patients.”